Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : INF108
Therapeutic Area : Gastroenterology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Infinant Health Announces Submission of Orphan Drug Designation Application
Details : Infinant Health's patented drug candidate is a Bifidobacterium longum subspecies infantis strain, INF108, being developed for the prevention of necrotizing enterocolitis in pre-term infants.
Product Name : INF108
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
February 04, 2024
Lead Product(s) : INF108
Therapeutic Area : Gastroenterology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable